Oxodipine

Suppliers

Names

[ Name ]:
Oxodipine

[Synonym ]:
Oxodipinum
IQB-837-V
Oxodipino [Spanish]
Oxodipinum [Latin]
Oxodipine [INN]
3,5-Pyridinedicarboxylic acid,1,4-dihydro-4-(1,3-benzodioxol-4-yl)-2,6-dimethyl-,ethyl methyl ester
Ethyl methyl 1,4-dihydro-2,6-dimethyl-4-(2,3-(methylenedioxy)phenyl)-3,5-pyridinedicarboxylate
OXODIPINE
Oxodipino

Chemical & Physical Properties

[ Density]:
1.247g/cm3

[ Boiling Point ]:
470ºC at 760 mmHg

[ Molecular Formula ]:
C₁₉H₂₁NO₆

[ Molecular Weight ]:
359.37300

[ Flash Point ]:
238ºC

[ Exact Mass ]:
359.13700

[ PSA ]:
83.09000

[ LogP ]:
2.71500

[ Index of Refraction ]:
1.552

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: US7968500

CHEMICAL NAME :: 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-(1,3-benzodioxol-4-yl)-2,6-dimethyl-, ethyl methyl ester

CAS REGISTRY NUMBER :: 90729-41-2

LAST UPDATED :: 199406

DATA ITEMS CITED :: 3

MOLECULAR FORMULA :: C19-H21-N-O6

MOLECULAR WEIGHT :: 359.41

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 1100 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 12,633,1987

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 150 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: FATOAO Farmakologiya i Toksikologiya (Moscow). For English translation, see PHTXA6 and RPTOAN. (V/O Mezhdunarodnaya Kniga, 113095 Moscow, USSR) V.2- 1939- Volume(issue)/page/year: 54(2),40,1991 ** OTHER MULTIPLE DOSE TOXICITY DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 2160 mg/kg/13W-I

TOXIC EFFECTS :: Vascular - BP lowering not characterized in autonomic section Endocrine - other changes Endocrine - changes in adrenal weight

REFERENCE :: TOPADD Toxicologic Pathology. (c/o Dr. F.A. de la Iglesia, Warner-Lambert Co., Pharmaceutical Research Div., POB 1047, Ann Arbor, MI 48106) V.6(3/4)- 1978- Volume(issue)/page/year: 20,549,1992

Related Compounds

4-(1-Acryloylpiperidine-4-carbonyl)-1-isobutyl-3-methylpiperazin-2-one
N-[3-[2-(2,4-Difluorophenyl)morpholin-4-yl]-3-oxopropyl]prop-2-enamide
1-[4-[2-(2-Hydroxyethyl)pyrrolidine-1-carbonyl]piperidin-1-yl]prop-2-en-1-one
N-(6-phenyl-2,3-dihydro-1H-inden-1-yl)-1-(prop-2-enoyl)piperidine-4-carboxamide
Methyl 3-methyl-3-[(1-prop-2-enoylpiperidine-4-carbonyl)amino]butanoate
1-(1-Prop-2-enoylpiperidine-4-carbonyl)-7-oxa-1-azaspiro[4.4]nonan-6-one
N-(1-Cyanocyclobutyl)-2-(2-methyl-3,5-dihydro-2H-1,4-benzoxazepin-4-yl)acetamide
2-[(2-chlorophenyl)(cyano)amino]-1-(3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)ethan-1-one
N-[(1,1-Dioxothiolan-2-yl)methyl]-4-(prop-2-enoylamino)benzamide
methyl (2S)-2-methyl-1-[3-(prop-2-enamido)propanoyl]pyrrolidine-2-carboxylate

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.